Elevidys Gene Therapy Shows Positive Results in Duchenne Muscular Dystrophy Trial

Sarepta Therapeutics announced positive topline results from the EMBARK phase 3 trial of its gene therapy Elevidys for Duchenne muscular dystrophy on June 18, 2024. The trial evaluated Elevidys in 125 ambulatory boys aged 4 to 7 years with Duchenne muscular dystrophy. Elevidys is designed to deliver a functional micro-dystrophin gene to muscle cells.

The trial met its primary endpoint, with Elevidys-treated patients showing a statistically significant improvement in North Star Ambulatory Assessment scores compared to placebo at week 52. The North Star Ambulatory Assessment measures motor function in Duchenne muscular dystrophy patients.

Secondary endpoints, including time to rise from the floor and 10-meter walk/run test, also favored the treatment group, though some did not reach statistical significance.

Muscular Dystrophy and Prior Treatments Duchenne

muscular dystrophy is a genetic disorder caused by mutations in the dystrophin gene, leading to progressive muscle weakness and loss of ambulation, typically by the early teens.

It affects approximately 1 in 3,500 to 5,000 male births worldwide. Without treatment, life expectancy is around 20 to 30 years due to respiratory and cardiac complications. The field has seen developments in exon-skipping therapies, which aim to restore partial dystrophin production by skipping mutated gene segments.

Sarepta's earlier exon-skipping drug eteplirsen received accelerated FDA approval in 2016 based on increased dystrophin levels, despite mixed clinical outcomes. Subsequent drugs like golodirsen and casimersen followed similar paths, but larger trials have shown limited functional benefits, raising questions about efficacy.

The EMBARK trial was a randomized, double-blind, placebo-controlled study conducted at multiple sites in the United States and Europe.

33 x 10^14 vector genomes per kilogram. Follow-up assessments occurred over 52 weeks, with ongoing monitoring for longer-term effects. Safety data indicated that Elevidys was generally well-tolerated, with most adverse events being mild to moderate.

Common side effects included vomiting, nausea, and elevated liver enzymes. Serious adverse events occurred in 4% of treated patients versus 3% in the placebo group. No treatment-related deaths were reported.

previously received accelerated FDA approval in 2023 for ambulatory patients aged 4 to 5 with confirmed dystrophin gene mutations.

The EMBARK results support potential expansion of the label to include patients up to age 7 and possibly non-ambulatory individuals. Sarepta plans to submit supplemental data to the FDA in the second half of 2024. The Duchenne community, including patients, families, and advocacy groups like Parent Project Muscular Dystrophy, has expressed cautious optimism.

Regulatory decisions will determine broader access, while additional trials are needed to assess long-term durability and effects in older patients. Ongoing research explores combination therapies to address unmet needs in this progressive disease.